ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 2440

Using Patient-Relevant Variables to Describe the Disease Course in Children with Juvenile Idiopathic Arthritis

Jaime Guzman1, Andrew Henrey2, Thomas Loughin2, Roberta Berard3, Natalie Shiff4, Roman Jurencak5, Susanne Benseler6, Lori B. Tucker7 and ReACCh-Out Investigators, 1Rheumatology, Division of Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, 2Statistics and Actuarial Science, Simon Fraser University, Burnaby, BC, Canada, 3Children's Hospital of Western Ontario, London, ON, Canada, 4Pediatric Rheumatology, University of Saskatchewan, Saskatoon, SK, Canada, 5University of Ottawa, Ottawa, ON, Canada, 6Alberta Children's Hospital Research Institute/University of Calgary, Calgary, AB, Canada, 7Rheumatology, BC Children's Hospital, Vancouver, BC, Canada

Meeting: ACR/ARHP Annual Meeting 2015

Date of first publication: September 29, 2015

Keywords: Clinical research, Disease Sub-phenotyping, Juvenile Arthritis, patient outcomes and quality of life

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: To define distinct disease course groups among children with Juvenile Idiopathic Arthritis (JIA) based on observed changes in quality of life, pain, medication requirements, medication side-effects and active joint counts (AJC) during the first 5 years of the disease. These variables were prioritized by patients, parents and clinicians in a previous study.

Methods: We used data from the Research in Arthritis in Canadian Children emphasizing Outcomes (ReACCh-Out) prospective inception cohort. We included 618 children newly diagnosed with JIA between 2005 and 2010 with information for at least 6 of 8 study visits within the first 5 years after diagnosis. Health-related quality of life and pain were measured with 10 cm visual analogue scales. Each current medication was given a weight and weights were added to obtain a medication requirements score. Medication side effects were reported using the Juvenile Arthritis Quality of Life Questionnaire and were weighted according to how frequently they were experienced by the child to obtain a side-effects score. AJC were reported by the attending pediatric rheumatologist. We grouped patients by course using multivariable cluster analysis and K-means clustering. Silhouette coefficients, R-Square statistics and clinical judgment were used to select the ideal number of clusters. The frequency of each disease course was described by JIA category.

Results: Four clusters provided the best discrimination: 1) Mild (43.0% of children)-almost normal quality of life throughout the disease course with initial mild pain and low AJC requiring minimal treatment, followed by normalization; 2) Moderate (33.7%)-moderate initial impact on quality of life and mild to moderate pain and AJC, followed by normalization; 3) Severe Controlled (11.6%)-moderate initial impact on quality of life and moderate pain levels with high AJC requiring aggressive treatment, followed by normalization; 4) Severe Persisting (11.6%)-persisting mayor impact on quality of life and moderate pain with moderate decreasing AJC, but ongoing treatment needs and side-effects. Children with oligoarthritis most often followed a Mild course. Almost half the children with RF negative polyarthritis, systemic and psoriatic JIA followed a Moderate course. Children with RF positive polyarthritis most often followed a Severe Controlled course. The Severe Persisting course was observed in all JIA categories but it was infrequent in systemic JIA and oligoarthritis.

Table: Proportion of children in each JIA category stratified by disease course cluster

JIA Category

Mild

Moderate

Severe Controlled

Severe Persisting

Oligoarthritis (n=228)

68.4

24.6 

0.9

6.1

RF-negative polyarthritis (n=130)

21.5

46.9 

17.7

13.8

Enthesitis-related (n=81)

37.0

29.6 

14.8

18.5

Systemic (n=47)

23.4

48.9

25.5

2.1

Psoriatic (n=38)

36.8

47.4 

2.6

13.2

RF-positive polyarthritis (n=26)

3.8

23.1 

61.5

11.5

Undifferentiated (n=68)

38.2

29.4 

8.8

23.5

Conclusion: Using patient-relevant variables the course of JIA can be described by four disease course groups with two of them reflecting a severe disease course, one that responded to treatment despite severe initial presentation and one with persisting impact on quality of life and pain despite moderate decreasing AJC. JIA category alone does not predict disease course.


Disclosure: J. Guzman, None; A. Henrey, None; T. Loughin, None; R. Berard, None; N. Shiff, None; R. Jurencak, None; S. Benseler, None; L. B. Tucker, None.

To cite this abstract in AMA style:

Guzman J, Henrey A, Loughin T, Berard R, Shiff N, Jurencak R, Benseler S, Tucker LB. Using Patient-Relevant Variables to Describe the Disease Course in Children with Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/using-patient-relevant-variables-to-describe-the-disease-course-in-children-with-juvenile-idiopathic-arthritis/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2015

ACR Meeting Abstracts - https://acrabstracts.org/abstract/using-patient-relevant-variables-to-describe-the-disease-course-in-children-with-juvenile-idiopathic-arthritis/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology